Filing Details

Accession Number:
0001209191-15-029051
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-03-24 21:50:37
Reporting Period:
2015-03-20
Filing Date:
2015-03-24
Accepted Time:
2015-03-24 21:50:37
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1178879 Amicus Therapeutics Inc FOLD Pharmaceutical Preparations (2834) 200422823
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1510394 Enrique Dilone 1 Cedar Brook Drive
Cranbury NJ 08512
Vp, Technical Operations No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-03-20 14,045 $11.51 64,045 No 4 M Direct
Common Srock Disposition 2015-03-20 14,045 $11.51 50,000 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options (right to buy) Disposition 2015-03-20 3,250 $0.00 3,250 $4.16
Common Stock Stock Options (right to buy) Disposition 2015-03-20 1,896 $0.00 1,896 $4.38
Common Stock Stock Options (right to buy) Disposition 2015-03-20 2,624 $0.00 2,624 $3.53
Common Stock Stock Options (right to buy) Disposition 2015-03-20 3,463 $0.00 3,463 $2.52
Common Stock Stock Options (right to buy) Disposition 2015-03-20 2,812 $0.00 2,812 $2.45
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
9,750 2013-11-01 2019-11-16 No 4 M Direct
33,104 2013-06-04 2022-06-04 No 4 M Direct
25,376 2014-01-28 2023-01-28 No 4 M Direct
31,537 2014-06-18 2023-06-18 No 4 M Direct
42,188 2015-01-03 2024-01-03 No 4 M Direct
Footnotes
  1. The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2014.
  2. This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.17 to $11.90. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
  3. This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.17 to $11.90. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.